Glaukos Corporation
GKOS
株式のランク
#2115
Glaukos Corporation operates as an ophthalmic medical technology and... Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
株価
$164.43
最終同期: 2026-10-16
時価総額
$9.70B
変化（1日）
-0.95%
変化（1年）
88.63%
国
US
取引 Glaukos Corporation (GKOS)
カテゴリー
Healthcare
Glaukos Corporation（GKOS）のEPS
June 2026 時点のEPS TTM: $-3.25
Glaukos Corporationの最新の財務報告と株価によると、同社の現在のEPS（TTM）は$-3.25です。2023年末には、EPSは$-2.78で、2022年のEPS$-2.09と増加でした。
Glaukos CorporationのEPS履歴（2012から2026まで）
各年末時点のEPS
| 年 | EPS | 変化 |
|---|---|---|
| 2026 (TTM) | $-3.25 | 17.33% |
| 2024 | $-2.77 | -0.36% |
| 2023 | $-2.78 | 33.01% |
| 2022 | $-2.09 | 95.33% |
| 2021 | $-1.07 | -60.37% |
| 2020 | $-2.70 | -758.54% |
| 2019 | $0.41 | -210.81% |
| 2018 | $-0.37 | 13,603.70% |
| 2017 | 0.00 | -101.93% |
| 2016 | $0.14 | -106.57% |
| 2015 | $-2.13 | 334.69% |
| 2014 | $-0.49 | -3.92% |
| 2013 | $-0.51 | -94.76% |
| 2012 | $-9.73 | 0.00% |
同様の企業または競合他社のEPS
| 企業 | EPS | EPSの差 | 国 |
|---|---|---|---|
| $3.11 | -195.69% |
US
|
|
| $3.59 | -210.46% |
IE
|
|
| $9.73 | -399.38% |
US
|
|
| $2.48 | -176.31% |
US
|
|
| - | - |
DE
|
